HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Status:
Terminated
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This is a research study to evaluate treatment of metastatic melanoma patients with a
combination of drugs. The combination being studied is vemurafenib (also known as Zelboraf®)
and High Dose Interleukin-2 (abbreviated as HD IL-2 and known as Proleukin®). The combination
of vemurafenib and HD IL-2 immunotherapy may enhance the response.